how big is Bajaj Healthcare?

As of March 2024, Bajaj Healthcare Ltd has a market capitalization of 1,662.38 Cr, with net sales of 542.60 Cr and net profit of 39.49 Cr over the last four quarters. Shareholder's funds are 278.36 Cr, and total assets amount to 743.27 Cr.

Market Cap: Bajaj Healthcare Ltd has a market capitalization of 1,662.38 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 542.60 Cr, and the sum of Net Profit for the same period is 39.49 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in March 2024. Shareholder's Funds are reported at 278.36 Cr, and Total Assets amount to 743.27 Cr.

Who are in the management team of Bajaj Healthcare?

As of March 2020, the management team of Bajaj Healthcare includes Sanjankumar R Bajaj (Chairman & Managing Director), Anil C Jain (Joint Managing Director), and several other directors and independent members responsible for the company's operations and strategy.

As of March 2020, the management team of Bajaj Healthcare includes the following individuals:<BR><BR>1. Sanjankumar R Bajaj - Chairman & Managing Director<BR>2. Anil C Jain - Joint Managing Director<BR>3. Namrata S Bajaj - Whole-time Director<BR>4. Dhananjay S Halte - Whole-time Director<BR>5. Rupesh H Nikam - Whole Time Director & CFO<BR>6. Ram B Banarase - Independent Director<BR>7. Hemant R Karnik - Independent Director<BR>8. Aakashkumar Kesari - Company Secretary<BR>9. Avinash Dalal - Independent Director<BR>10. Loukik D Tipnis - Independent Director<BR>11. Luke Benedict Fernandez - Independent Director<BR>12. Kejal Shah - Independent Director<BR>13. Pakshal Jain - Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

When is the next results date for Bajaj Healthcare?

No Upcoming Board Meetings

What is the bonus history of the Bajaj Healthcare?

Bajaj Healthcare announced a 1:1 bonus issue on April 9, 2019, with a record date of April 10, 2019, granting shareholders one additional share for each share held.

Bajaj Healthcare has a bonus history that includes a 1:1 bonus issue announced on April 9, 2019. The record date for this bonus was April 10, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Bajaj Healthcare declared dividend?

Yes, Bajaj Healthcare Ltd has declared a 20% dividend, amounting to ₹1 per share, with an ex-date of September 23, 2024. The company has shown strong total returns over various periods, including a 310.14% return over the last 5 years.

Bajaj Healthcare Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Bajaj Healthcare experienced a price return of 21.85%, with no dividend return, resulting in a total return of 21.85%.<BR><BR>Over the past year, the company saw a price return of 81.69% and a dividend return of 0.32%, leading to a total return of 82.01%.<BR><BR>In a 2-year period, the price return was 76.99%, with a dividend return of 0.64%, culminating in a total return of 77.63%.<BR><BR>For the 3-year period, the price return stood at 67.82%, while the dividend return was 1.26%, resulting in a total return of 69.08%.<BR><BR>In the 4-year timeframe, the price return was 36.62%, with a dividend return of 1.04%, leading to a total return of 37.66%.<BR><BR>Over the last 5 years, Bajaj Healthcare achieved a remarkable price return of 307.08% and a dividend return of 3.06%, resulting in a total return of 310.14%.<BR><BR>Overall, Bajaj Healthcare's dividend declaration reflects a commitment to returning value to shareholders, and the substantial total returns across various periods indicate strong performance and growth potential for the company.

Who are the peers of the Bajaj Healthcare?

Bajaj Healthcare's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. In terms of performance, Bajaj Healthcare has a strong 1-year return of 85.57%, while its peers show varying management risks and growth rates.

Peers: The peers of Bajaj Healthcare are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Jagsonpal Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, while Average management risk is found at Jagsonpal Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, and Remus Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Bajaj Healthcare, Torrent Pharma, Hester Bios, Bliss GVS Pharma, and Themis Medicare show below average growth. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Jagsonpal Pharma, while Bajaj Healthcare and Hester Bios have an average and below average capital structure, respectively.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Themis Medicare has the lowest at -34.36%. Bajaj Healthcare's 1-year return of 85.57% is significantly higher than both. Additionally, Hester Bios, Themis Medicare, and Remus Pharma have negative six-month returns.

What does Bajaj Healthcare do?

Bajaj Healthcare Ltd is a small-cap bulk drug manufacturer in the Pharmaceuticals & Biotechnology industry, established in 1993 and publicly listed since 2016, with recent quarterly net sales of ₹1,545 Cr and a net profit of ₹112 Cr. Key financial metrics include a P/E ratio of 38.00 and a market cap of ₹1,704 Cr.

Overview:<BR>Bajaj Healthcare Ltd is a bulk drug manufacturer operating in the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History:<BR>Bajaj Healthcare Ltd was established in 1993 and became a public company in 2005. It listed its shares on the Indian stock exchanges in 2016. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,545 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 112 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 1,704 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 38.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.19% <BR>Debt Equity: 0.41 <BR>Return on Equity: 9.67% <BR>Price to Book: 3.79 <BR><BR>Contact Details:<BR>Address: 602-606 Bhoomi Velocity Infote, Road No 23 Wagle Indl Estate Thane Maharashtra : 400604 <BR>Tel: 91-22-66177400/401 <BR>Email: investors@bajajhealth.com <BR>Website: http://www.bajajhealth.com

Who are the top shareholders of the Bajaj Healthcare?

The top shareholders of Bajaj Healthcare include Sajankumar Rameshwarlal Bajaj with 37.59%, individual investors with 26.72%, and institutional investors, including mutual funds at 1.64% and foreign institutional investors at 1.05%. The largest public shareholder is Vanaja Sundar Iyer, holding 2.22% of the shares.

The top shareholders of Bajaj Healthcare include the promoters, with Sajankumar Rameshwarlal Bajaj holding the highest stake at 37.59%. Additionally, individual investors collectively own 26.72% of the shares. The company also has some institutional investment, with mutual funds holding 1.64% through one scheme and foreign institutional investors (FIIs) holding 1.05% across ten different entities. The highest public shareholder is Vanaja Sundar Iyer, who holds 2.22% of the shares.

Are Bajaj Healthcare latest results good or bad?

Bajaj Healthcare's latest Q2 FY26 results are generally positive, with a net profit growth of 49.28% year-on-year and improved operating margins at 18.21%. However, a slight revenue decline of 0.62% from the previous quarter suggests caution is warranted moving forward.

Bajaj Healthcare's latest results for Q2 FY26 can be considered good overall, despite some mixed signals. The company reported a net profit of ₹12.45 crore, which represents a significant year-on-year growth of 49.28%. This indicates a strong recovery from previous performance levels. Additionally, the operating margin improved to 18.21%, up 175 basis points from the previous quarter, showcasing effective cost management.<BR><BR>On the revenue side, the company achieved ₹147.91 crore, reflecting an 11.14% increase year-on-year. However, there was a slight decline of 0.62% compared to the previous quarter, suggesting that while demand has stabilized, it hasn't necessarily expanded in the short term.<BR><BR>Overall, the positive aspects of margin expansion and strong year-on-year profit growth suggest that Bajaj Healthcare is navigating its challenges effectively, making its latest results more favorable than unfavorable. However, investors should remain cautious about the slight revenue decline and monitor future performance closely.

Is Bajaj Healthcare overvalued or undervalued?

As of November 7, 2025, Bajaj Healthcare is considered overvalued with a PE ratio of 27.28, significantly higher than its peers like Cipla and Dr. Reddy's Labs, and has underperformed the Sensex with a year-to-date return of -24.7%.

As of 7 November 2025, Bajaj Healthcare's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 27.28, an EV to EBITDA of 18.91, and a PEG ratio of 0.83, which suggests that while the company is growing, its valuation may not be justified by its earnings growth prospects.<BR><BR>In comparison to its peers, Bajaj Healthcare's PE ratio is notably higher than Cipla's 22.33, which is rated attractive, and Dr. Reddy's Labs at 17.43, also attractive. This indicates that Bajaj Healthcare is trading at a premium relative to these competitors despite not offering a significantly better growth outlook. Additionally, the stock has underperformed against the Sensex in the year-to-date period, with a return of -24.7% compared to the Sensex's 6.50%, further reinforcing the notion that the stock may be overvalued in the current market environment.

How has been the historical performance of Bajaj Healthcare?

Bajaj Healthcare's historical performance has shown significant fluctuations, with net sales peaking at 645.80 Cr in Mar'23 but declining to 542.60 Cr by Mar'25, alongside decreases in profit metrics and cash flow, despite an increase in total assets. Overall, the company has faced both growth and challenges in its financial performance.

Answer:<BR>The historical performance of Bajaj Healthcare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Bajaj Healthcare's net sales have experienced variability, peaking at 645.80 Cr in Mar'23 before declining to 542.60 Cr in Mar'25. The total operating income followed a similar trend, with a high of 679.89 Cr in Mar'22 and a decrease to 542.60 Cr in Mar'25. Raw material costs rose from 291.33 Cr in Mar'19 to 307.11 Cr in Mar'25, while total expenditure, excluding depreciation, increased from 327.55 Cr in Mar'19 to 460.17 Cr in Mar'25. Operating profit (PBDIT) fluctuated, reaching a high of 143.23 Cr in Mar'21 but dropping to 101.83 Cr in Mar'25. Profit before tax saw a significant decline from 118.82 Cr in Mar'21 to 46.01 Cr in Mar'25, with profit after tax also decreasing from 83.11 Cr in Mar'21 to 42.93 Cr in Mar'25. The company's total assets increased from 342.95 Cr in Mar'20 to 814.15 Cr in Mar'25, while total liabilities rose from 182.57 Cr in Mar'21 to 272.27 Cr in Mar'25. Cash flow from operating activities showed a decline from 43.00 Cr in Mar'21 to 21.00 Cr in Mar'25, with net cash inflow remaining stable at 0.00 Cr in Mar'25. Overall, Bajaj Healthcare's financial performance reflects a mix of growth and challenges over the years.

Is Bajaj Healthcare technically bullish or bearish?

As of December 1, 2025, Bajaj Healthcare's technical trend has shifted to a moderate bearish stance, indicated by bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Bajaj Healthcare is bearish with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. The KST shows a mildly bullish signal on the weekly but remains mildly bearish on the monthly, indicating some divergence. Overall, the lack of strong signals from the RSI and Dow Theory further supports the bearish outlook.

Should I buy, sell or hold Bajaj Healthcare?

Why is Bajaj Healthcare falling/rising?

As of 12-Dec, Bajaj Healthcare Ltd's stock price is at 413.30, with a slight increase of 0.16%. However, the stock has underperformed significantly over various periods, showing a year-to-date decline of 29.11% and declining investor interest, indicating ongoing challenges despite some positive indicators.

As of 12-Dec, Bajaj Healthcare Ltd's stock price is currently at 413.30, reflecting a slight increase of 0.65 (0.16%). Despite this minor rise, the stock has shown a negative performance over various periods, including a decline of 1.27% over the past week and a significant drop of 8.00% over the past month. Year-to-date, the stock has decreased by 29.11%, which starkly contrasts with the Sensex's gain of 9.12% during the same timeframe.<BR><BR>The stock is trading lower than its moving averages across multiple timeframes, indicating a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 66.64% compared to the 5-day average, suggesting reduced interest from investors. The stock is also close to its 52-week low, being only 3.7% away from Rs 398.<BR><BR>While there are some positive indicators, such as a significant growth in profit after tax (PAT) and attractive valuations compared to peers, these are overshadowed by the company's weak long-term fundamentals. The operating profits have shown a negative compound annual growth rate (CAGR) of -5.62% over the last five years, and the high debt to EBITDA ratio of 2.59 times raises concerns about the company's ability to service its debt.<BR><BR>Overall, despite a slight uptick in the stock price today, the broader context of consistent underperformance against benchmarks and declining investor interest suggests that Bajaj Healthcare's stock is facing significant challenges, leading to its overall negative trajectory.

Which are the latest news on Bajaj Healthcare?